NBIX vs. LLY
NBIX (Neurocrine Biosciences, Inc.) and LLY (Eli Lilly and Company) are both stocks. Both are in the Healthcare sector — NBIX in Drug Manufacturers - Specialty & Generic, LLY in Drug Manufacturers - General. Over the past 10 years, NBIX returned 13.85%/yr vs 33.16%/yr for LLY. At a 0.25 correlation, their price movements are largely independent.
Performance
NBIX vs. LLY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NBIX achieves a 24.87% return, which is significantly higher than LLY's 10.97% return. Over the past 10 years, NBIX has underperformed LLY with an annualized return of 13.85%, while LLY has yielded a comparatively higher 33.16% annualized return.
NBIX
- 1D
- -1.91%
- 1M
- 8.85%
- 6M
- 30.43%
- YTD
- 24.87%
- 1Y
- 32.71%
- 3Y*
- 21.73%
- 5Y*
- 12.33%
- 10Y*
- 13.85%
LLY
- 1D
- -2.33%
- 1M
- 2.38%
- 6M
- 12.13%
- YTD
- 10.97%
- 1Y
- 50.94%
- 3Y*
- 40.33%
- 5Y*
- 39.60%
- 10Y*
- 33.16%
NBIX vs. LLY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NBIX Neurocrine Biosciences, Inc. | 24.87% | 3.90% | 3.60% | 10.31% | 40.24% | -11.14% | -10.83% | 50.53% | -7.96% | 100.49% |
LLY Eli Lilly and Company | 10.97% | 40.25% | 33.30% | 60.91% | 34.26% | 66.08% | 31.04% | 16.14% | 40.45% | 17.83% |
Correlation
The correlation between NBIX and LLY is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.27 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.28 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.25 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.27 |
Correlation (All Time) Calculated using the full available price history since May 23, 1996 | 0.25 |
Fundamentals
NBIX:
$17.81B
LLY:
$1.12T
NBIX:
$6.50
LLY:
$28.16
NBIX:
27.23
LLY:
42.21
NBIX:
0.54
LLY:
0.85
NBIX:
5.87
LLY:
14.77
NBIX:
5.37
LLY:
34.13
NBIX:
$3.10B
LLY:
$72.25B
NBIX:
$3.05B
LLY:
$59.75B
NBIX:
$881.20M
LLY:
$32.97B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NBIX vs. LLY — Risk / Return Rank
NBIX
LLY
NBIX vs. LLY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NBIX | LLY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.34 | ||
| Sortino ratioReturn per unit of downside risk | -0.44 | ||
| Omega ratioGain probability vs. loss probability | 1.20 | 1.26 | -0.06 |
| Calmar ratioReturn relative to maximum drawdown | 1.50 | 2.23 | -0.72 |
| Martin ratioReturn relative to average drawdown | 3.29 | 5.56 | -2.27 |
Loading charts...
Drawdowns
NBIX vs. LLY - Drawdown Comparison
The maximum NBIX drawdown since its inception was -97.21%, which is greater than LLY's maximum drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for NBIX and LLY.
Loading charts...
Drawdown Indicators
| NBIX | LLY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.21% | -68.24% | -28.97% |
Max Drawdown (1Y)Largest decline over 1 year | -20.90% | -23.18% | +2.28% |
Max Drawdown (3Y)Largest decline over 3 years | -42.89% | -34.48% | -8.41% |
Max Drawdown (5Y)Largest decline over 5 years | -42.89% | -34.48% | -8.41% |
Max Drawdown (10Y)Largest decline over 10 years | -46.39% | -34.48% | -11.91% |
Current DrawdownCurrent decline from peak | -1.91% | -3.80% | +1.89% |
Average DrawdownAverage peak-to-trough decline | -43.74% | -19.19% | -24.55% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.52% | 9.27% | +0.25% |
Volatility
NBIX vs. LLY - Volatility Comparison
The current volatility for Neurocrine Biosciences, Inc. (NBIX) is 8.08%, while Eli Lilly and Company (LLY) has a volatility of 9.93%. This indicates that NBIX experiences smaller price fluctuations and is considered to be less risky than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NBIX | LLY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.08% | 9.93% | -1.85% |
Volatility (6M)Calculated over the trailing 6-month period | 23.42% | 27.64% | -4.22% |
Volatility (1Y)Calculated over the trailing 1-year period | 31.73% | 38.71% | -6.98% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 32.83% | 32.51% | +0.32% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 39.03% | 30.30% | +8.73% |
Dividends
NBIX vs. LLY - Dividend Comparison
NBIX has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.54%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
LLY Eli Lilly and Company | 0.54% | 0.56% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% |
NBIX Neurocrine Biosciences, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
NBIX vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NBIX vs. LLY - Profitability Comparison
NBIX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Neurocrine Biosciences, Inc. reported a gross profit of 800.70M and revenue of 814.50M. Therefore, the gross margin over that period was 98.3%.
LLY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Eli Lilly and Company reported a gross profit of 15.64B and revenue of 19.80B. Therefore, the gross margin over that period was 79.0%.
NBIX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Neurocrine Biosciences, Inc. reported an operating income of 193.40M and revenue of 814.50M, resulting in an operating margin of 23.7%.
LLY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Eli Lilly and Company reported an operating income of 9.19B and revenue of 19.80B, resulting in an operating margin of 46.4%.
NBIX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Neurocrine Biosciences, Inc. reported a net income of 197.90M and revenue of 814.50M, resulting in a net margin of 24.3%.
LLY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Eli Lilly and Company reported a net income of 7.40B and revenue of 19.80B, resulting in a net margin of 37.4%.
Frequently Asked Questions
NBIX and LLY have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LLY has higher volatility (9.93%) compared to NBIX (8.08%). In terms of maximum drawdown, NBIX dropped -97.21% vs LLY's -68.24%.
LLY currently has the higher Sharpe Ratio (1.33 vs 0.99), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NBIX and LLY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer